(Q36743909)

English

Granulocyte-macrophage colony-stimulating factor potentiates rituximab in patients with relapsed follicular lymphoma: results of a phase II study

scientific article published on 21 April 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

16 August 2017

Granulocyte-macrophage colony-stimulating factor potentiates rituximab in patients with relapsed follicular lymphoma: results of a phase II study (English)

1 reference

Europe PubMed Central

16 August 2017

1 reference

based on heuristic

inferred from title

follicular lymphoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Guillaume Cartron

1

1 reference

Europe PubMed Central

16 August 2017

Lu Zhao-Yang

2

1 reference

Europe PubMed Central

16 August 2017

Marion Baudard

3

1 reference

Europe PubMed Central

16 August 2017

Tarik Kanouni

4

1 reference

Europe PubMed Central

16 August 2017

Valérie Rouillé

5

1 reference

Europe PubMed Central

16 August 2017

Philippe Quittet

6

1 reference

Europe PubMed Central

16 August 2017

Bernard Klein

7

1 reference

Europe PubMed Central

16 August 2017

Jean-Francois Rossi

8

1 reference

Europe PubMed Central

16 August 2017

language of work or name

0 references

publication date

21 April 2008

1 reference

Europe PubMed Central

16 August 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

16 August 2017

26

1 reference

Europe PubMed Central

16 August 2017

16

1 reference

Europe PubMed Central

16 August 2017

2725-2731

1 reference

Europe PubMed Central

16 August 2017

Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2443403

29 September 2017

Expression and role of Fc- and complement-receptors on human dendritic cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2443403

29 September 2017

Tolerability and safety of rituximab (MabThera).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2443403

29 September 2017

From the bench to the bedside: ways to improve rituximab efficacy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2443403

29 September 2017

Human plasmacytoid-derived dendritic cells and the induction of T-regulatory cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2443403

29 September 2017

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2443403

29 September 2017

New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2443403

29 September 2017

IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2443403

29 September 2017

Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2443403

29 September 2017

Granulocyte-macrophage colony-stimulating factor (GM-CSF), given concurrently with induction therapy for acute myelogenous leukemia (AML), augments the syndrome of T-lymphocyte recovery

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2443403

29 September 2017

World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2443403

28 June 2018

The enigmatic plasmacytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD40-ligand

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2443403

28 June 2018

Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2443403

28 June 2018

Granulocyte-macrophage colony-stimulating factor enhances phagocytosis of bacteria by human neutrophils

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2443403

28 June 2018

A new schedule of CHOP/rituximab plus granulocyte-macrophage colony-stimulating factor is an effective rescue for patients with aggressive lymphoma failing autologous stem cell transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2443403

5 September 2018

Predictive value of Follicular Lymphoma International Prognostic Index (FLIPI) in patients with follicular lymphoma at first progression.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2443403

5 September 2018

Follicular lymphoma international prognostic index.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2443403

5 September 2018

Flt3 ligand and granulocyte-macrophage colony-stimulating factor preferentially expand and stimulate different dendritic and T-cell subsets.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2443403

5 September 2018

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2443403

5 September 2018

Salvage treatment after failure or relapse following initial chemotherapy for follicular non-Hodgkin's lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2443403

5 September 2018

Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2443403

4 December 2018

Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model

1 reference

https://pubmed.ncbi.nlm.nih.gov/18427151

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Induction of macrophage tumoricidal activity by granulocyte-macrophage colony-stimulating factor

1 reference

https://pubmed.ncbi.nlm.nih.gov/18427151

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Granulocyte-macrophage colony-stimulating factor enhances selective effector functions of tissue-derived macrophages

1 reference

https://pubmed.ncbi.nlm.nih.gov/18427151

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recombinant human granulocyte-macrophage colony-stimulating factor in patients with advanced malignancy: a phase Ib trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/18427151

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of the effects of IL-3, granulocyte-macrophage colony-stimulating factor, and macrophage colony-stimulating factor in supporting monocyte differentiation in culture. Analysis of macrophage antibody-dependent cellular cytotoxicity

1 reference

https://pubmed.ncbi.nlm.nih.gov/18427151

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Human recombinant granulocyte-macrophage colony-stimulating factor augments viability and cytotoxic activities of human monocyte-derived macrophages in long-term cultures

1 reference

https://pubmed.ncbi.nlm.nih.gov/18427151

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/18427151

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The induction of distinct cytokine cascades correlates with different effects of granulocyte-colony stimulating factor and granulocyte/macrophage-colony-stimulating factor on the lymphocyte compartment in the course of high-dose chemotherapy for bre

1 reference

https://pubmed.ncbi.nlm.nih.gov/18427151

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma--a randomized phase II trial of the Minnie Pearl Cancer Research Network

1 reference

https://pubmed.ncbi.nlm.nih.gov/18427151

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/18427151

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory foll

1 reference

https://pubmed.ncbi.nlm.nih.gov/18427151

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene

1 reference

https://pubmed.ncbi.nlm.nih.gov/18427151

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2007.13.7729

1 reference

Europe PubMed Central

16 August 2017

1 reference

Europe PubMed Central

16 August 2017

1 reference

Europe PubMed Central

16 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36743909&oldid=1561103986"